E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
advanced or metastatic cholangiocarcinoma FGFR2 gene fusion, FGFR genetic alteration |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10008593 |
E.1.2 | Term | Cholangiocarcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Cohort 1: To evaluate the efficacy of single agent BGJ398 in patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or translocations or other FGFR genetic alterations assessed by central imaging review as per RECIST v1.1. |
|
E.2.2 | Secondary objectives of the trial |
Cohort 1: -To further evaluate the efficacy of single agent BGJ398 as measured by overall response assessed by investigator, progression free survival, best overall response, disease control assessed by investigator and by central imaging review as per RECIST 1.1; and overall survival. - To characterize the safety and tolerability of single agent BGJ398 by the type, frequency and severity of AEs & SAEs.
Overall study: - To determine selected trough and 2-hr or 4-hr plasma concentrations of BGJ398 -to characterize the pharmocokinetic profile of BGJ398 FMI III and FMI IV formulations |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients with histologically or cytologically confirmed cholangiocarcinoma at the time of diagnosis. Patients with cancers of the gallbladder or ampulla of Vater are not eligible. • Written documentation of local laboratory or central laboratory determination of the following FGFR gene alterations from a sample collected before BGJ398 treatment: - Cohort 1: FGFR2 gene fusions or translocations - Cohort 2: one of the following: (a) FGFR1 fusions or translocations, (b) FGFR3 fusions or translocations, or (c) FGFR1/2/3 mutation known to be an activating mutation and noted in Appendix 4 - Cohort 3: FGFR2 gene fusions or translocations • Patients must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced or metastatic disease. Patients should have had evidence of progressive disease following prior regimen, or if prior treatment discontinued due to toxicity must have continued evidence of measurable disease • ECOG performance status ≤ 1 (Patients with ECOG performance status of 2 may be considered on a case-by-case basis after discussion with QED Therapeutics). • Cohort 3 only: Documented prior treatment with FGFR inhibitor other than BGJ398/infigratinib. |
|
E.4 | Principal exclusion criteria |
• Prior or current treatment with a mitogen-activated protein kinase (MEK) inhibitor (all cohorts), BGJ398/infigratinib (all cohorts), or selective FGFR inhibitor (Cohorts 1 and 2 only). • Current evidence of significant corneal or retinal disorder/keratopathy including, but not limited to, bullous/band keratopathy, inflammation or ulceration, keratoconjuctivitis, confirmed by ophthalmic examination • History and/or current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, vascular system, and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcification • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral BGJ398 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection) • Current evidence of endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis etc. • Concurrently receiving or planning to receive during participation in this study, treatment with agents that are known strong inhibitors or inducers of CYP3A4. Medications which increase serum phosphorus and/or calcium concentration are excluded. Patients are not permitted to receive enzyme-inducing anti-epileptic drugs. • Cohort 3 only: Known existence of a V564F mutation in the FGFR2 gene.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall response rate (ORR) is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR), as per RECIST version 1.1. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline, then every 8 weeks, until disease progression or study discontinuation |
|
E.5.2 | Secondary end point(s) |
Cohort 1: 1- Overall survival 2- Progression free survival 3- Best overall response 4- Disease control rate 5- Number of participants with adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability
Overall study: 6-Selected trough and 2-hr or 4-hr Plasma concentration profile |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1- Every 4 months for one year after discontinuation of study treatment 2- Baseline, then every 8 weeks until disease progression or the initiation of subsequent anticancer therapies or death whichever occurs first 3- Baseline, then every 8 weeks, until disease progression or study discontinuation 4- Baseline, then every 8 weeks, until disease progression or study discontinuation 5- Starting from date of signing the consent form to 30 days afer the last dose 6- From First dose of study treatment to study discontinuation |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
France |
Germany |
Italy |
Japan |
Korea, Republic of |
Russian Federation |
Singapore |
Spain |
Taiwan |
Thailand |
Turkey |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study is defined as the time when the last patient completes the survival follow-up as described in the protocol or when the last patient on study has expired, been lost to follow up, or withdraws consent, whichever occurs first or when the study is terminated early. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 29 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 29 |